S. Kim

530 total citations
12 papers, 436 citations indexed

About

S. Kim is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, S. Kim has authored 12 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in S. Kim's work include Renal cell carcinoma treatment (8 papers), Cancer Genomics and Diagnostics (6 papers) and Pancreatic and Hepatic Oncology Research (2 papers). S. Kim is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Cancer Genomics and Diagnostics (6 papers) and Pancreatic and Hepatic Oncology Research (2 papers). S. Kim collaborates with scholars based in United States, United Kingdom and Poland. S. Kim's co-authors include Melissa Fazzari, Philip O. Livingston, Grace E. Ungers, Kathryn L. Terry, Samuel J. Danishefsky, Howard I. Scher, Kenneth O. Lloyd, Sucharita Adluri, Maria Spassova and W. G. BORNMANN and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

S. Kim

11 papers receiving 427 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Kim United States 7 300 176 128 97 91 12 436
Jennifer Macaluso United States 8 350 1.2× 63 0.4× 170 1.3× 41 0.4× 75 0.8× 9 539
Jason L. Rowand United States 5 251 0.8× 80 0.5× 125 1.0× 21 0.2× 30 0.3× 6 369
Dongweon Song United States 9 219 0.7× 79 0.4× 157 1.2× 16 0.2× 47 0.5× 11 414
Jean-Christophe Eymard France 6 122 0.4× 348 2.0× 228 1.8× 24 0.2× 40 0.4× 12 478
Sonia Garofalo Italy 6 145 0.5× 126 0.7× 189 1.5× 27 0.3× 74 0.8× 7 364
Yu Kataoka Japan 6 213 0.7× 99 0.6× 176 1.4× 22 0.2× 43 0.5× 10 378
J. C. Bendell United States 13 261 0.9× 82 0.5× 208 1.6× 20 0.2× 30 0.3× 37 413
Ivar Bleumer Netherlands 9 307 1.0× 253 1.4× 205 1.6× 15 0.2× 152 1.7× 13 527
Dan Chan United States 6 250 0.8× 194 1.1× 287 2.2× 24 0.2× 43 0.5× 13 532
Ben Staal United States 9 219 0.7× 62 0.4× 140 1.1× 22 0.2× 39 0.4× 14 365

Countries citing papers authored by S. Kim

Since Specialization
Citations

This map shows the geographic impact of S. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Kim more than expected).

Fields of papers citing papers by S. Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Kim. The network helps show where S. Kim may publish in the future.

Co-authorship network of co-authors of S. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of S. Kim. A scholar is included among the top collaborators of S. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Kim. S. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Escudier, Bernard, M. Dror Michaelson, Robert J. Motzer, et al.. (2014). Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. British Journal of Cancer. 110(12). 2821–2828. 79 indexed citations
2.
Cohen, Ezra E.W., Michael A. Tortorici, S. Kim, et al.. (2014). A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemotherapy and Pharmacology. 74(6). 1261–1270. 42 indexed citations
3.
Twelves, Chris, Ewa Chmielowska, Libor Havel, et al.. (2013). Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Annals of Oncology. 25(1). 132–138. 30 indexed citations
4.
5.
Estilo, Cherry L., et al.. (2012). Oropharyngeal Cancer Patients and Mandibular Dose Distributions Following Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 84(3). S481–S482. 1 indexed citations
6.
Motzer, Robert J., Bernard Escudier, Piotr Tomczak, et al.. (2012). Axitinib vs Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors. Annals of Oncology. 23. ix262–ix262. 10 indexed citations
7.
Motzer, Robert J., T. De La Motte Rouge, Andrea Harzstark, et al.. (2011). Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial.. Journal of Clinical Oncology. 29(15_suppl). 4547–4547. 13 indexed citations
8.
Rixe, Olivier, Janice P. Dutcher, Robert J. Motzer, et al.. (2009). Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). Journal of Clinical Oncology. 27(15_suppl). 5045–5045. 40 indexed citations
9.
Spano, Jean-Philippe, Miranda A. Moore, S. Kim, et al.. (2006). A phase I study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer. Journal of Clinical Oncology. 24(18_suppl). 13092–13092. 6 indexed citations
10.
Motzer, Robert J., Brian I. Rini, M. Dror Michaelson, et al.. (2006). SUNITINIB MALATE (SU11248) – EFFICACY IN RENAL CELL CARCINOMA (RCC). European Urology Supplements. 5(2). 287–287.
11.
Beaumont, Jennifer L., David Cella, Robert J. Motzer, et al.. (2005). Patient reported outcomes in a phase 2 trial of SU11248 for metastatic renal cell carcinoma. Journal of Clinical Oncology. 23(16_suppl). 8167–8167. 4 indexed citations
12.
Slovin, Susan F., Govindaswami Ragupathi, Sucharita Adluri, et al.. (1999). Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proceedings of the National Academy of Sciences. 96(10). 5710–5715. 209 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer Macaluso Breakdown of academic impact, for papers by Jason L. Rowand Breakdown of academic impact, for papers by Dongweon Song Breakdown of academic impact, for papers by Jean-Christophe Eymard Breakdown of academic impact, for papers by Sonia Garofalo Breakdown of academic impact, for papers by Yu Kataoka Breakdown of academic impact, for papers by J. C. Bendell Breakdown of academic impact, for papers by Ivar Bleumer Breakdown of academic impact, for papers by Dan Chan Breakdown of academic impact, for papers by Ben Staal
Rankless by CCL
2026